Analytical Data
-
Gene name
GAGE5
- Application
-
Alternative Names
Cancer/testis antigen 4.5 ;CT4.5
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13069
-
Expression Region
1-117aa
-
Molecular Weight
39.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The GAGE5 protein is a member of the GAGE (Gage Antigen) gene family, known for its expression in various cancers and its potential as a target for cancer immunotherapy. This family of proteins is characterized by their ability to elicit immune responses, particularly in the context of tumors, making them valuable candidates for vaccine development. GAGE5, as a cancer/testis (CT) antigen, primarily expresses in the testes and certain malignancies, thereby evading immune detection in normal tissues. Research into GAGE5 has gained attention due to its limited expression in healthy adult tissues, which reduces the likelihood of autoimmunity when targeting this protein in cancer treatment. Studies have shown that GAGE5 can induce robust T-cell responses, highlighting its potential in personalized cancer vaccines and adoptive T-cell therapies. Furthermore, understanding the functional mechanisms of GAGE5, including its role in tumor progression and immune evasion, could provide insights into broader therapeutic strategies. Given its immunogenic properties and restricted expression profile, GAGE5 represents a promising avenue in the development of effective cancer treatments, particularly in the realm of immunotherapy.
